|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP17 was overexpressed in both squamous and adenocarcinoma NSCLC tissue.
|
24123619 |
2013 |
|
Tumor Progression
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
|
25776484 |
2015 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
|
25776484 |
2015 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Dub3 is a deubiquitinating enzyme.It is highly expressed in tumor-derived cell lines and has an established role in tumor proliferation.
|
25776484 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dub3 expression was significantly associated with lymph node metastasis and clinical staging (P<0.05).
|
25776484 |
2015 |
|
Childhood Solid Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
USP17 is a novel deubiquitinating enzyme that is differentially expressed in certain types of solid tumor.
|
26777424 |
2016 |
|
Adult Solid Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP17 is a novel deubiquitinating enzyme that is differentially expressed in certain types of solid tumor.
|
26777424 |
2016 |
|
Solid Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
USP17 is a novel deubiquitinating enzyme that is differentially expressed in certain types of solid tumor.
|
26777424 |
2016 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
USP17 was more highly expressed in low grade (I+II) glioma than high-grade (III+IV) glioma (p<0.001).
|
26777424 |
2016 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation.
|
28198361 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Dub3 is overexpressed in breast cancer; knockdown of Dub3 resulted in Snail1 destabilization, suppressed EMT and decreased tumour cell migration, invasion, and metastasis.
|
28198361 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28288134 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28288134 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28650472 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28650472 |
2017 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
USP17 expression in lung cancers was associated with poor prognosis, macrophage, and inflammatory marker expressions.
|
30038267 |
2018 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
|
30057199 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer.
|
30778200 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
USP17 Suppresses Tumorigenesis and Tumor Growth through Deubiquitinating AEP.
|
30906206 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
USP17 Suppresses Tumorigenesis and Tumor Growth through Deubiquitinating AEP.
|
30906206 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases.
|
31534019 |
2019 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
|
30718431 |
2019 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
|
30718431 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
|
30718431 |
2019 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
As a novel Hippo pathway regulator, DUB3 has the potential to act a tumor suppressor by limiting YAP activity.
|
28061504 |
2017 |